Collegium Pharmaceutical Files 8-K on Security Holder Vote

TL;DR

Collegium Pharma (COLL) filed an 8-K for a shareholder vote meeting. Details TBD.

AI Summary

On May 16, 2024, Collegium Pharmaceutical, Inc. filed an 8-K report indicating a submission of matters to a vote of security holders. The filing does not contain specific details about the matters to be voted on or any associated financial figures.

Why It Matters

This filing signals that Collegium Pharmaceutical is convening a meeting where shareholders will vote on important company matters, which could impact the company's future direction.

Risk Assessment

Risk Level: low — The filing is procedural and does not disclose any new financial information or significant operational changes that would immediately impact the company's risk profile.

Key Players & Entities

• Collegium Pharmaceutical, Inc. (company) — Registrant
• May 16, 2024 (date) — Date of earliest event reported
• 100 Technology Center Drive Suite 300 (address) — Principal executive offices
• Stoughton, MA 02072 (address) — Principal executive offices
• 781-713-3699 (phone_number) — Registrant's telephone number

FAQ

Key Financial Figures

• $0.001 — ch registered Common stock, par value $0.001 per share COLL The NASDAQ Global Sele

Filing Documents

• tm2414882d1_8k.htm (8-K) — 36KB
• 0001104659-24-063396.txt ( ) — 206KB
• coll-20240516.xsd (EX-101.SCH) — 3KB
• coll-20240516_lab.xml (EX-101.LAB) — 33KB
• coll-20240516_pre.xml (EX-101.PRE) — 22KB
• tm2414882d1_8k_htm.xml (XML) — 4KB

07 Submission

Item 5.07 Submission of Matters to a Vote of Security Holders. On May 16, 2024, Collegium Pharmaceutical, Inc. (the "Company") held its 2024 Annual Meeting of Shareholders (the "Annual Meeting"). A total of 32,705,747 shares of common stock of the Company were entitled to vote as of March 27, 2024, the record date for the Annual Meeting, of which 31,059,529 were present in person or by proxy at the Annual Meeting. The following is a summary of the final voting results for each matter presented to shareholders. PROPOSAL 1 : Election of eight Directors to hold office until the 2025 Annual Meeting of Shareholders. Nominee For Against Abstentions Broker Non-Votes Rita Balice-Gordon 28,105,388 568,305 24,995 2,360,841 Garen Bohlin 28,404,221 268,899 25,568 2,360,841 John Fallon 25,399,411 3,273,949 25,328 2,360,841 John Freund 28,384,244 289,466 24,978 2,360,841 Michael Heffernan 26,121,329 2,552,363 24,996 2,360,841 Neil McFarlane 28,442,938 230,764 24,986 2,360,841 Gwen Melincoff 28,081,458 592,076 25,154 2,360,841 Gino Santini 28,284,684 389,000 25,004 2,360,841 Each of Rita Balice-Gordon, Garen Bohlin, John Fallon, John Freund, Michael Heffernan, Neil McFarlane, Gwen Melincoff, and Gino Santini was re-elected by the Company's shareholders as Directors to hold office until the 2025 Annual Meeting of Shareholders. PROPOSAL 2: Approval of, on an advisory basis, the compensation of the Company's named executive officers. For Against Abstentions Broker Non-Votes 28,311,783 350,755 36,150 2,360,841 On an advisory basis, the Company's shareholders approved the compensation of the Company's named executive officers. PROPOSAL 3 : Ratification of the appointment of Deloitte & Touche LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2024. For Against Abstentions Broker Non-Votes 30,106,217 92,255

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Dated: May 20, 2024 Collegium Pharmaceutical, Inc. By: /s/ Colleen Tupper Name: Colleen Tupper Title: Executive Vice President and Chief Financial Officer

View Full Filing

View this 8-K filing on SEC EDGAR